imatinib

1 stories · following the connections

Business

LB-100 and LB-102, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors

By Nasdaq OMXFeb 9, 2018, 2:45 PM UTC